United States · Bill · HR
H.R. 2335 (114th)
Stop Tampering of Prescription Pills Act of 2015
Introduced
14 May 2015
Last action
15 May 2015 · Referred
Status
Referred to the Subcommittee on Health.
Sponsors
Rep. Keating, William R. [D-MA-9], Rep. Rogers, Harold [R-KY-5], Rep. Rooney, Thomas J. [R-FL-17], Rep. Lynch, Stephen F. [D-MA-8], Rep. Aderholt, Robert B. [R-AL-4], Rep. Buchanan, Vern [R-FL-16], Rep. Kennedy, Joseph P., III [D-MA-4], Rep. McGovern, James P. [D-MA-2], Rep. Schakowsky, Janice D. [D-IL-9], Rep. Clark, Katherine M. [D-MA-5]
Subjects
Healthcare
Source updated
12 August 2025
Summary
Stop Tampering of Prescription Pills Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to deny approval to a new oral opioid (a drug with effects similar to opium, such as morphine) that does not have properties that make the drug significantly more difficult to abuse if an abuse-deterrent drug containing the same opioid is available. The FDA may approve an opioid drug that is not abuse-deterrent if approval is necessary to prevent or alleviate a drug shortage or to address a significant unmet public health need. To be approved by the FDA, a generic version of an abuse-deterrent brand name drug must be at least comparably abuse-deterrent and its active components must not differ in any material respect from the brand name drug. An approved generic drug is not bioequivalent to, and does not have the same therapeutic effect as, a brand name drug that becomes abuse-deterrent unless the generic drug is at least comparably abuse-deterrent. Approval of a generic oral opioid is withdrawn if the brand name drug is not abuse-deterrent and not available and there is an approved abuse-deterrent drug available that contains the same opioid in the same dose. Approval of an oral opioid is withdrawn if the drug is not abuse-deterrent and there is an approved abuse-deterrent drug available that contains the same opioid. Withdrawal of approval may be waived by the FDA for a drug intended for a special needs population. The FDA must delay withdrawal to give the drug sponsor an opportunity to obtain approval for an abuse-deterrent formulation of the drug.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
14 May 2015
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
14 May 2015
Introduced
Introduced in House
Source: IntroReferral
14 May 2015
Introduced
Introduced in House
Source: IntroReferral
15 May 2015
Referred
Referred to the Subcommittee on Health.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 14 May 2015 · Download file
Documents
3 official files
Introduced in House (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House (text)
Introduced in House · EN · 14 May 2015
Introduced in House (PDF)
Introduced in House · EN · 14 May 2015
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 14 May 2015
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Keating, William R. [D-MA-9] · D · Sponsor
- Rep. Rogers, Harold [R-KY-5] · R · Sponsor
- Rep. Rooney, Thomas J. [R-FL-17] · R · Sponsor
- Rep. Lynch, Stephen F. [D-MA-8] · D · Sponsor
- Rep. Aderholt, Robert B. [R-AL-4] · R · Sponsor
- Rep. Buchanan, Vern [R-FL-16] · R · Sponsor
- Rep. Kennedy, Joseph P., III [D-MA-4] · D · Sponsor
- Rep. McGovern, James P. [D-MA-2] · D · Sponsor
- Rep. Schakowsky, Janice D. [D-IL-9] · D · Sponsor
- Rep. Clark, Katherine M. [D-MA-5] · D · Cosponsor
- · hsif00 · Standing
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/114th-congress/house-bill/2335
- Open data entity: https://api.congress.gov/v3/bill/114/hr/2335
- us · 114-hr-2335 · source updated 12 August 2025